Ovarian Cancer: An Overview

What Ovarian Cancer Is

"Ovarian cancer" is a convenient label for what is really a family of distinct diseases that happen to arise in or near the ovary. The term covers several different malignancies that differ in their cell of origin, their molecular drivers, and their behavior. Most cases — and most deaths — come from epithelial carcinomas, and within that group high-grade serous carcinoma (HGSC) dominates the clinical picture. One of the more consequential shifts in our understanding over the past two decades is that many high-grade serous cancers don't begin in the ovary at all. They originate in the distal fallopian tube, from a precursor lesion called serous tubal intraepithelial carcinoma (STIC), and seed the ovary and peritoneum secondarily. That detail isn't academic trivia; it reframes how we think about prevention and where the disease is actually hiding when we go looking for it.

How Common Ovarian Cancer Is

In absolute terms, ovarian cancer is uncommon. The American Cancer Society projects roughly 21,010 new cases in the United States in 2026, accounting for about 1.0% of new cancer diagnoses [2]. A woman's lifetime risk sits near 1.1%, or about 1 in 91 [1]. The age-adjusted incidence rate was 10.4 per 100,000 women per year for 2019–2023 [1].

So why does this relatively rare cancer command so much attention? Because it kills out of proportion to how often it occurs. An estimated 12,450 deaths are projected for 2026, making it the 14th leading cause of cancer death overall and the deadliest of the gynecologic malignancies [2]. The trends, though, are quietly encouraging: incidence has been declining by roughly 1% per year, and mortality is falling faster, around 2.7% per year, reflecting both a shift toward earlier-stage diagnosis and genuine gains in treatment [1].

Ovarian Cancer Risk Factors

Risk here is mostly a story of biology and inheritance rather than lifestyle, which can be frustrating for patients who want something actionable. The strongest signals are genetic, and the single most important question in any new diagnosis is whether a hereditary syndrome is in play — it changes management for the patient and screening for the family. Beyond genetics, reproductive and hormonal history shapes risk in ways that are statistically real but individually modest.

Factors that raise risk and are not modifiable include:

• Germline BRCA1/2 mutations and homologous recombination deficiency (HRD) — the major hereditary contributors. These same alterations also predict benefit from a specific drug class, which is why they sit at the center of both risk assessment and therapy planning [1].
• Lynch syndrome (mismatch-repair deficiency), which raises risk particularly for endometrioid and clear cell histotypes.
• Family history, especially a first-degree relative with ovarian or breast cancer.
• Age and reproductive history — most diagnoses fall between 55 and 64, with nulliparity, early menarche, and late menopause adding incremental risk.
• Endometriosis, linked to the clear cell and endometrioid subtypes.

On the other side of the ledger, several factors are genuinely protective and reflect lifetime ovulatory burden: parity, breastfeeding, oral contraceptive use, and tubal ligation or salpingectomy all lower risk [1]. The protective effect of removing the fallopian tubes fits neatly with what we now know about where high-grade serous disease begins.

How Ovarian Cancer Is Found

Here's the central, unsolved problem: we don't have an effective way to detect ovarian cancer early in the general population, and that gap drives most of the mortality burden. The U.S. Preventive Services Task Force recommends against screening average-risk, asymptomatic women, concluding that CA-125 testing and transvaginal ultrasound don't reduce deaths and do cause harm through false positives and unnecessary surgery [3]. For women at high genetic risk, management is individualized and may include risk-reducing salpingo-oophorectomy — but that is a different conversation from population screening [3].

Investigators continue to test combinations of serial CA-125 measurements interpreted by risk algorithms, ultrasound, and newer circulating biomarkers, but none has yet demonstrated the mortality benefit that would justify routine use. Part of the difficulty is biological: by the time a high-grade serous cancer is large enough to register on these tests, it has frequently already spread.

That leaves us leaning on symptoms, which is a weak position. Presentation tends to be vague and nonspecific — bloating, pelvic or abdominal pain, early satiety, urinary urgency — the kind of complaints that get attributed to a dozen benign causes before anyone orders imaging. In practice, by the time symptoms prompt a serious workup, the disease has often been present for months. The consequence shows up in the staging data: about 49% of cases are still diagnosed at distant stage, though that figure has improved from roughly 57% a decade earlier [1].

Ovarian Cancer Survival by Stage

Survival tracks stage closely, which is exactly why the screening gap matters so much. The overall five-year relative survival is about 51%, a number pulled down by how often the disease is caught late [1]. When it is found early, the outlook is dramatically better. Before the numbers, an essential caveat: these are population-level relative survival figures from large cohorts. They describe groups, not individuals. They cannot account for a particular person's histotype, molecular profile, response to therapy, or overall health, and no one should read their own prognosis off this table.

With that understood, five-year relative survival by stage at diagnosis is approximately [1]:

• Localized disease: ~93%
• Regional spread: ~75%
• Distant disease: ~31%

The cliff between localized and distant is the whole argument for earlier detection — and the whole reason the absence of a good screening test is so costly.

Diagnosing Ovarian Cancer and Its Subtypes

Because "ovarian cancer" is several diseases, diagnosis is fundamentally an exercise in classification, not just confirmation. Pathologists distinguish the major epithelial histotypes — high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous carcinoma — because these aren't interchangeable. They differ in natural history, in chemosensitivity, and in prognosis: high-grade serous tends to present late but responds initially to platinum-based therapy, while low-grade serous behaves more indolently yet resists conventional chemotherapy. Getting the histotype right is therefore prognostically meaningful, not a labeling formality.

Immunohistochemistry and molecular testing sharpen that distinction and link it to therapy. WT1 and aberrant p53 staining help confirm serous histology; napsin A and HNF1-beta point toward clear cell; HER2 matters in the mucinous subtype; and mismatch-repair or MSI testing flags dMMR tumors. Most consequentially, BRCA1/2 status — germline and somatic — and the broader HRD phenotype identify patients whose tumors may be vulnerable to a PARP-inhibitor class of drugs, which is where classification stops being descriptive and starts directing eligibility for treatment.

The Central Tension

Ovarian cancer sits at an uncomfortable intersection: it is biologically heterogeneous, it usually announces itself too late, and we still lack any screening test that reliably catches it early in the general population. Yet the trajectory is genuinely improving — mortality is falling faster than incidence, more cancers are being found before they disseminate, and molecular profiling now matches specific tumors to targeted drug classes in a way that was unavailable a generation ago. The fallopian-tube origin of high-grade serous disease may turn out to be the most actionable insight we have, shifting the prevention conversation away from detecting established cancer and toward removing the tissue where it begins. For now, the most useful thing this overview can convey is that the answer to "what kind of ovarian cancer" matters as much as the diagnosis itself.

References

1. National Cancer Institute. SEER Cancer Stat Facts. seer.cancer.gov/statfacts; SEER*Explorer. 2026 release (2019–2023 incidence; 2020–2024 mortality; 2016–2022 survival).
2. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026. doi:10.3322/caac.70043.
3. US Preventive Services Task Force. Ovarian Cancer: Screening (2018 Recommendation). uspreventiveservicestaskforce.org. 2018.